Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel
Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
LMB‐100 is a novel immune‐conjugate (immunotoxin) that targets mesothelin. A phase 1/2 clinical trial was conducted (NCT02810418) with primary objectives assessing the safety and efficacy of LMB‐100 ± nab‐paclitaxel. Participant blood samples were analyzed for changes in serum cytokines and circulating immune cell subsets associated with response o...
Alternative Titles
Full title
Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b0426dc9f76e4ee5ac65fe73a10166c9
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b0426dc9f76e4ee5ac65fe73a10166c9
Other Identifiers
ISSN
2045-7634
E-ISSN
2045-7634
DOI
10.1002/cam4.5290
